Human mitochondrial DNA (mtDNA) is a 16,569-bp circular double-stranded DNA molecule that encodes 13 subunits of the respiratory chain complexes, two ribosomal RNAs, and 22 transfer RNAs. Each nucleated human cell contains a few thousand copies of mtDNA. The somatic mutation rate of mtDNA is presumed to be 10 to 20 times higher than that of nuclear DNA, due to close proximity to the site of reactive oxygen species formation, lack of histones and relatively decreased capacity for repair ([@Wallace1992]). There is increasing evidence that mitochondrial gene mutations including large deletions, missense, frameshift mutations, and small deletions/insertions are associated with various types of cancer ([@Polyaketal1998]; [@Flissetal2000]; [@Pentaetal2001]; [@Modica-NapolitanoandSingh2004]; [@AralandOzer2007]). Among these mutations, a specific deletion of 4977 bp, called the \`common deletion\' (ΔmtDNA^4977^ mutation), was examined in several human tumors as well as in several metabolic and neurodegenerative disorders, but the results were inconsistent ([@Maximoetal2002]; [@Abnetetal2004]; [@Danietal2004]; [@Zhuetal2004]; [@Yeetal2008]). The deletion removes a 4977 bp section of mitochondrial DNA that encompasses five tRNA genes and seven polypeptide genes which encode sub-units of cytochrome c oxidase, complex I and ATPase, between nucleotide positions 8470 and 13447, involving two 13 bp repeats ([@SoongandArnheim1996]). In this study, we investigated the association of the mtDNA common deletion in Turkish patients with breast, colorectal and thyroid tumors.

Paraffin-embedded tissue specimens from primary tumors and matched non-neoplastic adjacent tissues were selected from a total of 100 cancer patients. Briefly, 6 μm thick sections were cut from blocks that had been selected for maximal tumor content. Total DNA was isolated from these thin sections as described by [@SoongandIacopetta1997], following deparaffinization with xylene. Control DNA from blood samples of 49 healthy volunteers was also extracted, using proteinase K digestion followed by phenol/chloroform extraction ([@Johnetal1991]). The study was approved by the ethics committees at Marmara University, School of Medicine and Gulhane Military School of Medicine, Haydarpasa Teaching Hospital.

The mitochondrial common deletion was determined by two different techniques. Primer locations for each technique are schematized in [Figure 1a](#fig1){ref-type="fig"} and b. The first method involves two sets of primers: Mitout-F (5\'-CCCAACT AAATACTACCGTATGG-3\') and Mitout-R (5\'-GGCTC AGGCGTTTGTGTATGAT-3\') (outside the deletion region); and Mitin-F (5\'-CTGAGCCTTTTACCACTCCAG-3\') and Mitin-R (5\'-GGTGATTGATACTCCTGATGCG-3\') (within the deletion region) ([@SoongandArnheim1996]; [@Maximoetal2002]) ([Figure 1a](#fig1){ref-type="fig"}). In the wild-type mtDNA, only the Mitin primer set yields a PCR product with 142 bp. In cases with the mtDNA common deletion, Mitin primers amplify a 142-bp target sequence, and Mitout primers an aberrant PCR product with 214 bp. PCR amplifications were performed in a total volume of 25 μL containing 200 μmol/L of each dNTP, 12.5 pmol of each of the forward and reverse primers, 50 mmol/L KCl, 10 mmol/L Tris-HCl, (pH 9.0), 1.5 mmol/L MgCl~2~, and 1 U of *Taq* DNA polymerase (Fermentas, Lithuania). Cycling conditions included a single predenaturation step at 94 °C for 5 min, followed by 35 cycles of denaturation at 94 °C for 20 s, annealing at 60 °C for 20 s, elongation at 72 °C for 20 s, and a final incubation at 72 °C for 2 min. The PCR products were visualized on 2% agarose gels stained with ethidium bromide. Secondly, in order to exclude experimental false results and to detect extremely low levels of deletion, we applied a nested-PCR method ([@SoongandArnheim1996]). Primers MT1 (5\'-AATTCCCCTAAAA ATCTTTGAAAT-3\') and MT3 (5\'-AGGCGCTATCAC CACTCTTGTTCG-3\') were used for the primary PCR reaction (see Fig. 1b for primer positions). These primers are located just outside the 13 bp repeats where the deletion occurs. One microliter of this primary PCR reaction was then used as a template for the secondary reactions, using primers MT2 (5\'-GCGATGAGAGTAATAGATAGGGCTCA GGCG-3\') and MT3. Cycling conditions for both primary and secondary reactions were similar to those described for the first method. A 303 bp product was examined by electrophoresis on 2% agarose gels in the samples with the common deletion.

In this study, we searched for the presence of the mitochondrial 4977 bp common deletion in cancerous and healthy tissue samples from 25 breast, 25 colorectal and 50 thyroid cancer patients. Type or locations of the tumors, along with age and gender data of the patients are summarized in [Table 1](#t1){ref-type="table"}. The mean age of the breast cancer patients, who were all female, was 59 ± 13.8 years. Regarding colorectal cancer patients, the mean age was 62.4 ± 10.2 years, and 12 out of the 25 cases were male. The mean age of the thyroid cancer patients was 37.6 ± 15.8 years, with 27 male and 23 female patients. In all the breast and colorectal cancer samples, adjacent healthy tissues were available, but in seven of the thyroid cancer samples, there was no adjacent healthy tissue. Blood samples were obtained from 49 healthy volunteers (10 male and 39 female) with a mean age of 59.2 ± 12 years.

At first, we successfully amplified mitochondrial genome from all samples using the Mitin primer pair ([Figure 1a](#fig1){ref-type="fig"}), which allows amplification of wild-type mtDNA. Then, in order to determine the common deletion, samples including tumors, adjacent healthy tissues and healthy controls were amplified using the Mitout primer pairs, but no common deletion was detected. As previously mentioned by [@SoongandArnheim1996], to detect and measure low levels of deletion in tissues, high sensitivity as well as discrimination between the few molecules of deleted mtDNA and the overwhelming excess of wt-mtDNA molecules are required. These authors suggested concentrating the DNA sample, using radioactively labeled primers or nested-PCR to detect extremely low levels of deletion. In principle, by using the nested-PCR protocol, it is possible to concentrate deleted molecules at the first PCR step and detect single molecules. Thus, all samples (tumor and adjacent healthy tissues and control blood) were then re-amplified using the more sensitive nested-PCR method (see [Figure 1b](#fig1){ref-type="fig"}). The mtDNA common deletion was present in only six samples from thyroid cancer patients, whereas this deletion was not observed in the samples from breast or colorectal cancer patients or from healthy volunteers. The deletion-carrying cases are summarized in [Table 2](#t2){ref-type="table"}. As seen in this table, one case had the mutation in both the cancerous and its adjacent healthy tissues (case ID 69). Two cases had the common deletion in the cancerous tissues, but not in the healthy adjacent tissues (cases 33 and 68). One sample presenting the deletion (case ID 62) in the cancerous tissue had no matching adjacent healthy tissue available to be evaluated.

Previous studies concerning the mtDNA common deletion and cancer have shown inconsistent results. An association of the mtDNA common deletion with a variety of human cancers, including Hürthle cell carcinoma of the thyroid, esophageal squamous cell carcinoma, thyroid and hepatocellular cancers has been reported ([@Maximoetal2002]; [@Abnetetal2004]). In contrast, several studies showed no significant association with either lung or breast, head and neck, colorectal and gastric carcinomas ([@Danietal2004]; [@Zhuetal2004]; [@Yeetal2008]). This inconsistency may be due to the laboratory techniques applied and intrinsic features of samples available for each study (*e.g.,* fresh frozen tissue *versus* formalin fixed, age and ethnic background of patients, and so on), as noted by [@Yeetal2008]. The role of the mtDNA common deletion in carcinogenesis is so far not clear. The mutation may represent a functional disadvantage for the growth of tumor cells ([@Yeetal2008]). In the present study, we applied two PCR-based methods to investigate the association of the mtDNA common deletion with breast, colorectal and thyroid tumors in Turkish patients. The mitochondrial DNA common deletion was very rare in either the cancerous or non-tumoral tissues of the patient groups and in healthy controls, suggesting that the deletion is not related with the examined cancer types. The mitochondrial common deletion was detected in six thyroid tumor cases only by the nested-PCR method. This result shows that the method used to detect the mtDNA common deletion is crucial. Availability of both tumoral and non-tumoral adjacent tissues from almost all patients and the use of two different techniques were the strengths of this study. On the other hand, the relatively small number of patients was its main limitation, and further studies with larger cohorts are needed.
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###### 

Clinical characteristics of the study population.

                      Type of tumor                                    Mean age ± SD   No. of patients and gender
  ------------------- ------------------------------------------------ --------------- ----------------------------
  Breast cancer       Invasive ductal carcinoma                        56.4 ± 14.9     13 Females
                      Infiltrative ductal carcinoma                    56.1 ± 10.1     7 Females
                      Infiltrative apocrine carcinoma                  60              1 Female
                      Inflammatory lobular carcinoma                   77              1 Female
                      Ductal carcinoma in situ                         71              1 Female
                      Atypical medullary carcinoma                     77              1 Female
                      Unknown                                          77              1 Female
                                                                                       
  Colorectal cancer   Location of the tumor                            Mean age ± SD   No. of patients and gender
                                                                                       
                      Ascending colon                                  68 ± 25.4       2 Females
                      Descending colon                                 58 ± 14.8       4 Males
                      Cecum                                            59 ± 9.2        2 Males, 1 Female
                      Sigmoid colon                                    63 ± 8.4        1 Male, 3 Females
                      Rectum                                           58.5 ± 7.8      3 Males, 3 Females
                      Transverse colon                                 69.5 ± 7.7      2 Females
                      Recto-sigmoid region                             61              1 Female
                      Splenic flexure                                  73.5 ± 0.7      1 Male, 1 Female
                      Descending + sigmoid colon                       65              1 Male
                                                                                       
  Thyroid cancer      Type of tumor                                    Mean age ± SD   No. of patients and gender
                                                                                       
                      Papillary carcinoma                              40.2 ± 17.2     12 Males, 7 Females
                      Follicular adenoma                               35.9 ± 15.5     11 Males, 8 Females
                      Follicular carcinoma                             36 ± 17.3\*     3 Males, 2 Females
                      Medullary carcinoma                              38\*\*          1 Male, 1 Female
                      Anaplastic carcinoma                             50              1 Female
                      Oncocytic adenoma                                21              1 Male
                      Papillary carcinoma + Hashimoto\'s thyroiditis   26\*\*\*        2 Females
                      Unknown                                          unknown         1 Female

\*: Ages of one male and one female patients with follicular carcinoma were unknown.

\*\*: Age of one male patient with medullary carcinoma was unknown.

\*\*\*: Age of one female patient with papillary carcinoma + Hashimoto\'s thyroiditis was unknown.

###### 

Summary of the thyroid cancer cases carrying the mtDNA common deletion.

  Case ID   Type of tumor          Patient\'s age and gender   Tumor   Adjacent healthy tissue
  --------- ---------------------- --------------------------- ------- -------------------------
  33        Follicular adenoma     55, Female                  Yes     No
  43        Papillary carcinoma    61, Female                  No      Yes
  62        Papillary carcinoma    53, Male                    Yes     Not available
  63        Papillary carcinoma    44, Female                  No      Yes
  68        Papillary carcinoma    29, Male                    Yes     No
  69        Follicular carcinoma   27, Male                    Yes     Yes
